AGENDIA B V has a total of 15 patent applications. Its first patent ever was published in 2007. It filed its patents most often in WIPO (World Intellectual Property Organization), EPO (European Patent Office) and Canada. Its main competitors in its focus markets biotechnology are JILIN ENTRY EXIT INSPECTION AND QUARANTINE BUREAU OF THE PEOPLE S REPUBLIC OF CHINA, HARDIN SUSAN and SUI WEIGUO.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 5 | |
#2 | EPO (European Patent Office) | 4 | |
#3 | Canada | 2 | |
#4 | Australia | 1 | |
#5 | China | 1 | |
#6 | Mexico | 1 | |
#7 | New Zealand | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Measuring microorganism processes |
# | Name | Total Patents |
---|---|---|
#1 | Glas Annuska Maria | 11 |
#2 | Roepman Paul | 10 |
#3 | Van Zandwijk Nico | 3 |
#4 | Van T Veer Laura Johanna | 2 |
#5 | Van Laar Ryan | 1 |
#6 | Paul Roepman | 1 |
#7 | Tollenaar Robertus Alexandre Eduard Matheus | 1 |
#8 | Floore Arno Nicolaas | 1 |
#9 | Maria Glas Annuska | 1 |
#10 | Simon Iris | 1 |
Publication | Filing date | Title |
---|---|---|
EP2202320A1 | Methods and means for typing a sample comprising colorectal cancer cells | |
EP2159291A1 | Means and method for determining tumor cell percentage in a sample | |
WO2009002175A1 | A method of typing a sample comprising colorectal cancer cells | |
WO2008147205A1 | Prognostic gene expression signature for non small cell lung cancer patients |